Prothena Corporation plc

187 articles with Prothena Corporation plc

• Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023

  3/31/2023

  Prothena Corporation plc (NASDAQ:PRTA) today announced new preclinical data from its PRX012 program, a potential best-in-class anti-amyloid beta (Aβ) product candidate in development for the treatment of Alzheimer’s disease, at the 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD) in Gothenburg, Sweden.

• Prothena to Participate in Stifel 2023 Virtual CNS Days

  3/21/2023

  Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the Stifel 2023 Virtual CNS Days on Tuesday March 28, 2023 at 10:30 AM ET.

• Prothena to Highlight Next Generation Treatments for Alzheimer’s and Parkinson’s Disease at the AD/PD 2023 Meeting

  3/14/2023

  Prothena Corporation plc announced broad participation at the 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders being held March 28 – April 1, 2023 in Gothenburg, Sweden, highlighting Prothena's leadership in advancing next generation treatments for Alzheimer’s and Parkinson’s disease.

• Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights

  2/23/2023

  Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the fourth quarter and full year 2022.

• Prothena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

  2/16/2023

  Prothena Corporation plc, a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced that it will report its fourth quarter and full year 2022 financial results on Thursday, February 23, 2023 after the close of the U.S. financial markets.

• Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 03, 2023

  2/3/2023

  Prothena Corporation plc announced that in connection with hiring a new employee, the compensation committee of the Company’s board of directors granted the individual hired by the Company an option to purchase 85,000 ordinary shares of the Company.

• Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer’s Disease

  1/31/2023

  Prothena Corporation plc (NASDAQ:PRTA) today announced positive topline Phase 1 single ascending dose (SAD) study results for PRX005, a potentially best-in-class investigational tri-epitopic antibody for the treatment of Alzheimer’s disease that specifically binds with high affinity to the R1, R2, and R3 repeats within the microtubule binding region (MTBR) of tau and targets both 3R and 4R tau isoforms

• Prothena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares

  12/15/2022

  Prothena Corporation plc announced that it priced an underwritten public offering of 3,250,000 of its ordinary shares at a price to the public of $56.50 per ordinary share, before the underwriting discount and estimated offering expenses.

• Prothena Announces Proposed Public Offering of Ordinary Shares - December 13, 2022

  12/13/2022

  Prothena Corporation plc, a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced that it has commenced an underwritten public offering of 3,000,000 of its ordinary shares.

• Prothena Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022

  12/12/2022

  Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today presented data from the completed phase 3 VITAL study demonstrating that in a post hoc analysis of patients with Mayo Stage IV AL amyloidosis, a statistically significant survival benefit was observed in those treated with birtamimab at 9 months.

• Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy

  11/21/2022

  Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that the Company has earned a $40 million milestone payment from Novo Nordisk related to the continued advancement of NNC6019 (formerly PRX004) in a Phase 2 clinical study for the treatment of ATTR cardiomyopathy.

• Prothena Reports Third Quarter 2022 Financial Results and Business Highlights

  11/3/2022

  Prothena Corporation plc today reported financial results for the third quarter and first nine months of 2022 and provided a business update.

• Prothena to Present Data on Survival Benefit Observed in Completed Phase 3 Study of Drug Candidate Birtamimab in Patients with Mayo Stage IV AL Amyloidosis at the ASH 2022 Meeting

  11/3/2022

  Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will present survival data from the phase 3 VITAL study at an oral presentation at the American Society of Hematology Conference 2022 (ASH).

• Prothena to Report Third Quarter 2022 Financial Results on November 3rd

  10/27/2022

  Prothena Corporation plc (NASDAQ:PRTA) today announced that it will report its third quarter and first nine months of 2022 financial results on Thursday, November 3, 2022 after the close of the U.S. financial markets.

• Prothena to Participate in Upcoming Healthcare Conferences

  9/1/2022

  Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in the following upcoming investor conferences.

• Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors

  9/1/2022

  Prothena Corporation plc, a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced the appointment of Helen S. Kim, MBA, to its Board of Directors.

• Prothena Reports Second Quarter 2022 Financial Results and Business Highlights

  8/8/2022

  Prothena Corporation plc, a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, reported financial results and provided business highlights for the second quarter and first six months of 2022.

• Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 02, 2022

  8/2/2022

  Prothena Corporation plc announced that in connection with hiring a new employee, the compensation committee of the Company’s board of directors granted the individual hired by the Company an option to purchase 35,000 ordinary shares of the Company.

• Prothena to Report Second Quarter 2022 Financial Results on August 8th

  8/1/2022

  Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today that it will report its second quarter and first six months of 2022 financial results on Monday, August 8, 2022 after the close of the U.S. financial markets.

• Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 01, 2022

  7/1/2022

  Prothena Corporation plc announced that in connection with hiring two new employees, the compensation committee of the Company’s board of directors granted the individuals hired by the Company, in the aggregate, options to purchase 50,000 ordinary shares of the Company.